Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
Fortress Biotech (NASDAQ:FBIO) Pref A (FBIOP) stock has reached a new 52-week low, trading at $4.85, with an InvestingPro analysis revealing concerning financial metrics, including a -34.8% gross profit margin and revenue decline of -31.8% over the last twelve months. This latest price point marks a significant downturn for the company, which has seen its stock value decrease by 68.29% over the past year. Investors are closely monitoring the biopharmaceutical company’s performance, as it navigates through a challenging period marked by this notable decline. InvestingPro data highlights the company is quickly burning through cash, with an EBITDA of -$98.53M and analysts not anticipating profitability this year. The 52-week low serves as a critical indicator for the stock’s trajectory and has sparked discussions among shareholders regarding the company’s future prospects and potential strategies for recovery. With a current ratio of 1.27 and a beta of 1.83, InvestingPro analysis reveals 5 additional key insights about the company’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.